ASCELIA

AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

Our mission is to improve the life expectancy and quality of life for people living with cancer.

Our strategy is to develop and make available to patients a portfolio of differentiated, underappreciated and de-risked product candidates addressing unmet medical needs in cancer and cancer-related diseases.

Lead candidate Mangoral (phase III ready) is an MRI imaging drug being developed for detection and localization of liver metastases.

Oncoral (in phase I) is a novel tablet-based irinotecan formulation, intended for treatment of advanced gastric (stomach) cancer.

• 2019-02-20Ascelia Pharma publishes prospectus in connection with Initial Public Offering on Nasdaq Stockholm
• 2018-11-19Ascelia Pharma receives positive feedback from FDA on design of the pivotal Phase 3 study with Mangoral®
• 2018-11-13Encouraging results from clinical Phase I study of Oncoral presented in a new publication